Lord, Abbett & Co
TGTX icon

Lord, Abbett & Co’s TG Therapeutics TGTX Stock Holding History

Lord, Abbett & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-557,966
Closed -$20.1M – 579
2025
Q2 		$20.1M Buy
+557,966
New +$20.8M 0.06% 288
2022
Q1 		– Sell
-195,212
Closed -$3.71M – 688
2021
Q4 		$3.71M Sell
195,212
-1,118,576
-85% -$29M 0.01% 569
2021
Q3 		$43.7M Sell
1,313,788
-1,512,974
-54% -$46.8M 0.1% 286
2021
Q2 		$110M Sell
2,826,762
-1,868,539
-40% -$73.4M 0.26% 108
2021
Q1 		$226M Buy
4,695,301
+254,842
+6% +$12.2M 0.58% 25
2020
Q4 		$231M Sell
4,440,459
-558,067
-11% -$18.9M 0.61% 21
2020
Q3 		$134M Buy
4,998,526
+3,671,841
+277% +$84.5M 0.43% 52
2020
Q2 		$25.8M Buy
1,326,685
+380,921
+40% +$6.13M 0.09% 336
2020
Q1 		$9.31M Buy
+945,764
New +$11.9M 0.04% 452
2015
Q4 		– Sell
-234,829
Closed -$2.37M – 945
2015
Q3 		$2.37M Sell
234,829
-158,479
-40% -$2.36M 0.01% 829
2015
Q2 		$6.53M Buy
+393,308
New +$6.23M 0.02% 724

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lord, Abbett & Co's TGTX Position: Q3 2025 in Review

Lord, Abbett & Co sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 557,966 shares — an estimated $20.1M sold.

Lord, Abbett & Co first reported a position in TGTX in Q2 2015 and held it in 11 quarters. The position peaked at $231M in Q4 2020. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Lord, Abbett & Co reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 557,966 TG Therapeutics shares in Q3 2025, an estimated $20.1M.
  • Lord, Abbett & Co first reported a position in TG Therapeutics in Q2 2015 and held it in 11 quarters.
  • Lord, Abbett & Co's TG Therapeutics position peaked at $231M in Q4 2020.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Lord, Abbett & Co's 13F filing for Q3 2025, filed 13 Nov 2025.